Atherosclerotic Cardiovascular Disease
Plaque-driven narrowing/hardening of the arteries and its clinical consequences -- coronary heart disease, stroke, and peripheral artery disease -- primarily driven by hyperlipidemia/dyslipidemia and managed with lipid-lowering and antiplatelet/anticoagulant therapy.
Phase 1/2 and later readouts in Atherosclerotic Cardiovascular Disease, in your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Total attributable cost
$69.5B
$3,494/patient
Drug spend
$22.7B
$1,139/patient
All severities (2015-2018 NHANES cycle) · US